Pixantrone maleate for non-Hodgkin's lymphoma

Drugs of Today
Deborah Mukherji, Ruth Pettengell

Abstract

Pixantrone (BBR-2778) is a novel aza-anthracenedione anthracycline derivative developed by Cell Therapeutics Incorporated, WA, USA. Pixantrone is similar in structure to the anthracenedione mitoxantrone but lacks the 5, 8-dihydroxy substitution groups implicated in mitoxantrone-induced cardiotoxicity. The PIX301 phase III single-agent trial of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma randomized patients to receive either pixantrone or another single agent of the investigators' choice. The rate of confirmed and unconfirmed remissions in patients treated with pixantrone was significantly higher than in those receiving other agents, as was the overall response rate and progression-free survival. There is evidence that pixantrone is well tolerated when substituted for anthracyclines in combination regimens for aggressive non-Hodgkin's lymphoma with comparable rates of complete remission. Pixantrone has also been used for the treatment of indolent non-Hodgkin's lymphomas and the combination of pixantrone and rituximab has been shown to be superior to rituximab alone in relapsed or refractory disease in the phase III PIX302 study. On the basis of these data, the United States Food and Drug...Continue Reading

Citations

Sep 13, 2011·Expert Opinion on Drug Metabolism & Toxicology·Mariam Jamal-Hanjani, Ruth Pettengell
Jul 9, 2013·The Cochrane Database of Systematic Reviews·Gilad ItchakiMical Paul

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Expert Review of Hematology
Dionysios Papadatos-Pastos, Ruth Pettengell
Expert Opinion on Drug Metabolism & Toxicology
Mariam Jamal-Hanjani, Ruth Pettengell
Expert Opinion on Investigational Drugs
Loaie M El-Helw, Barry W Hancock
Expert Opinion on Pharmacotherapy
Deborah Mukherji, Ruth Pettengell
© 2021 Meta ULC. All rights reserved